

Drug Utilization Review (DUR) Meeting Minutes June 3, 2013

Members Present: Norman Byers, John Savageau, Leann Ness, Cheryl Huber, Greg Pfister, Jeffrey Hostetter, Tanya Schmidt, Steve Irsfeld

Members Absent: Todd Twogood, Russ Sobotta, James Carlson, Carrie Sorenson, Carlotta McCleary, Michael Booth

Medicaid Pharmacy Department: Brendan Joyce

HID Staff Present: Candace Rieth

Chair G. Pfister called the meeting to order at 1:00 pm. Chair G. Pfister asked for a motion to approve the minutes from the March meeting. C. Huber moved that the minutes be approved, and J. Savageau seconded the motion. Chair G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce informed the board members that the pharmacy program is performing well and appears to be under budget at this time. This is partly attributed to the brand/generic split. The generic utilization is approximately 84%. Over the next few years, the pharmacy budget will start growing due to specialty pharmacy growth. Currently, specialty pharmacy is growing approximately 20% per year. B. Joyce also discussed Medicaid Expansion. The legislature passed Medicaid Expansion and it will be put out for bid to MCOs at a per capita rate. State staff will oversee this operation. Expansion will begin January 1, 2014. There should be approximately 20,000 recipients.

Fulyzaq Second Review

A motion and second were made at the March meeting to place Fulyzaq on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Xeljanz Second Review

A motion and second were made at the March meeting to place Xeljanz on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Immediate Release Narcotic Utilization

B. Joyce reviewed utilization for immediate release narcotics. The goal is to ensure appropriate utilization and decrease diversion with these products. Examples of changes that can be made include quantity limits, drug-drug edits, and criteria for use of extended release products for patients using immediate release products long term. The future goal for these products would be one long-acting agent, one short-acting agent and one combo agent with acetaminophen. The board will review patient profiles during an executive session at the next meeting.

Rayos Review

B. Joyce reviewed Rayos clinical information with the board. There was no public comment. J. Hostetter made a motion to place Rayos on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

Diclegis Review

B. Joyce reviewed Diclegis clinical information with the board. There was no public comment. J. Savageau made a motion to place Diclegis on prior authorization. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

Sitavig Review

B. Joyce reviewed Sitavig clinical information with the board. There was no public comment. G. Pfister made a motion to place Sitavig on prior authorization. N. Byers seconded the motion. This topic will be brought up at the next meeting for finalization.

Onmel Review

B. Joyce reviewed Onmel clinical information with the board. There was no public comment. S. Irsfeld made a motion to place Onmel on prior authorization. T. Schmidt seconded the motion. This topic will be brought up at the next meeting for finalization.

Giazo Review

B. Joyce reviewed Giazo clinical information with the board. There was no public comment. J. Hostetter made a motion to place Giazo on prior authorization. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Delzicol Review

B. Joyce reviewed Delzicol clinical information with the board. There was no public comment. The department will review post rebate data to determine which drug is the best option (Asacol HD or Delzicol).

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Savageau moved to approve the new criteria and N. Byers seconded the motion. Chair G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held September 9, in Bismarck. C. Huber made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. G. Pfister adjourned the meeting.